Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs

As the recent development of high-throughput technologies in cancer pharmacogenomics, there is an urgent need to develop new computational approaches for comprehensive identification of new pharmacogenomic biomarkers, such as microRNAs (miRNAs). In this study, a network-based framework, namely the SMiR-NBI model, was developed to prioritize miRNAs as potential biomarkers characterizing treatment responses of anticancer drugs on the basis of a heterogeneous network connecting drugs, miRNAs and genes. A high area under the receiver operating characteristic curve of 0.820 ± 0.013 was yielded during 10-fold cross validation. In addition, high performance was further validated in identifying new anticancer mechanism-of-action for natural products and non-steroidal anti-inflammatory drugs. Finally, the newly predicted miRNAs for tamoxifen and metformin were experimentally validated in MCF-7 and MDA-MB-231 breast cancer cell lines via qRT-PCR assays. High success rates of 60% and 65% were yielded for tamoxifen and metformin, respectively. Specifically, 11 oncomiRNAs (e.g. miR-20a-5p, miR-27a-3p, miR-29a-3p, and miR-146a-5p) from the top 20 predicted miRNAs were experimentally verified as new pharmacogenomic biomarkers for metformin in MCF-7 or MDA-MB-231 cell lines. In summary, the SMiR-NBI model would provide a powerful tool to identify potential pharmacogenomic biomarkers characterized by miRNAs in the emerging field of precision cancer medicine, which is available at http://lmmd.ecust.edu.cn/database/smir-nbi/.

[1]  Tongbin Li,et al.  miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..

[2]  Yiwei Li,et al.  Regulating miRNA by natural agents as a new strategy for cancer treatment. , 2013, Current drug targets.

[3]  J. Hescheler,et al.  Modulation of miRNAs by natural agents: Nature’s way of dealing with cancer , 2015 .

[4]  Jie Shen,et al.  Adverse Drug Events: Database Construction and in Silico Prediction , 2013, J. Chem. Inf. Model..

[5]  Jianyi Li,et al.  Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[6]  Xia Li,et al.  SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression , 2013, Bioinform..

[7]  Ana Kozomara,et al.  miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..

[8]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[9]  Longhua Chen,et al.  MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma. , 2015, International journal of radiation oncology, biology, physics.

[10]  A. Alizadeh,et al.  MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer. , 2016, Life sciences.

[11]  Chi-Ying F. Huang,et al.  miRTarBase: a database curates experimentally validated microRNA–target interactions , 2010, Nucleic Acids Res..

[12]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[13]  Y. Wang,et al.  OCT4 as a target of miR-34a stimulates p63 but inhibits p53 to promote human cell transformation , 2014, Cell Death and Disease.

[14]  M. Disney,et al.  Small molecule chemical probes of microRNA function. , 2015, Current opinion in chemical biology.

[15]  A. Hatzigeorgiou,et al.  TarBase: A comprehensive database of experimentally supported animal microRNA targets. , 2005, RNA.

[16]  E. Olson,et al.  MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles , 2012, Nature Reviews Drug Discovery.

[17]  Jie Li,et al.  Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space , 2013, J. Chem. Inf. Model..

[18]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[19]  Klaus Pantel,et al.  Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients , 2012, Breast Cancer Research and Treatment.

[20]  Howard L McLeod,et al.  Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed , 2013, Science.

[21]  Jie Shen,et al.  Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs). , 2013, Molecular bioSystems.

[22]  Jasjit K. Banwait,et al.  Contribution of bioinformatics prediction in microRNA-based cancer therapeutics. , 2015, Advanced drug delivery reviews.

[23]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Jeannette Bigler,et al.  Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.

[25]  George A Calin,et al.  Small molecule compounds targeting miRNAs for cancer therapy. , 2015, Advanced drug delivery reviews.

[26]  Noam Shomron,et al.  MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. , 2011, Trends in molecular medicine.

[27]  A. Gavin,et al.  SnapShot: Protein-Protein Interaction Networks , 2011, Cell.

[28]  G. Schratt,et al.  microRNA involvement in developmental and functional aspects of the nervous system and in neurological diseases , 2009, Neuroscience Letters.

[29]  Andrey Golubov,et al.  Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin , 2010, International journal of cancer.

[30]  Stefano Volinia,et al.  Interferon modulation of cellular microRNAs as an antiviral mechanism , 2007, Nature.

[31]  Jing Wang,et al.  Psmir: a database of potential associations between small molecules and miRNAs , 2016, Scientific Reports.

[32]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[33]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[34]  Jie Li,et al.  SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug–target interactions and drug repositioning , 2016, Briefings Bioinform..

[35]  Russell Bowler,et al.  The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations , 2014, Nucleic acids research.

[36]  M. Nakajima,et al.  microRNAs as mediators of drug toxicity. , 2013, Annual review of pharmacology and toxicology.

[37]  M. Ingelman-Sundberg,et al.  Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. , 2009, Pharmacogenomics.

[38]  C. Klinge.  miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets , 2015, Molecular and Cellular Endocrinology.

[39]  Alexander Deiters,et al.  Small Molecule Modifiers of the microRNA and RNA Interference Pathway , 2010, The AAPS Journal.

[40]  Qing Wu,et al.  miREnvironment Database: providing a bridge for microRNAs, environmental factors and phenotypes , 2011, Bioinform..

[41]  Most Mauluda Akhtar,et al.  Bioinformatic tools for microRNA dissection , 2015, Nucleic acids research.

[42]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[43]  F. Yu,et al.  MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival , 2012, PloS one.

[44]  C E Lipscomb,et al.  Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.

[45]  Noam Shomron,et al.  MicroRNAs and pharmacogenomics. , 2010, Pharmacogenomics.

[46]  S. Zhong,et al.  MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. , 2013, Gene.

[47]  Jie Li,et al.  Computational prediction of microRNA networks incorporating environmental toxicity and disease etiology , 2014, Scientific Reports.

[48]  Jing Wang,et al.  Identifying novel associations between small molecules and miRNAs based on integrated molecular networks , 2015, Bioinform..

[49]  Gary D. Bader,et al.  An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.

[50]  M. Eileen Dolan,et al.  Cancer pharmacogenomics: strategies and challenges , 2012, Nature Reviews Genetics.

[51]  Huixiao Hong,et al.  microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment. , 2015, Biomarkers in medicine.

[52]  Q. Cui,et al.  Sulindac inhibits tumor cell invasion by suppressing NF-κB mediated transcription of microRNAs , 2012, Oncogene.

[53]  Urs A Meyer,et al.  Omics and drug response. , 2013, Annual review of pharmacology and toxicology.

[54]  Feixiong Cheng,et al.  Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory science. , 2015, Biomarkers in medicine.

[55]  David L. Wheeler,et al.  GenBank , 2015, Nucleic Acids Res..

[56]  W. Gallagher,et al.  miRNA dysregulation in breast cancer. , 2013, Cancer research.

[57]  Yadi Zhou,et al.  Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method , 2012, PloS one.